SCHEMBL7908141

SCHEMBL7908141

CSc1ccc(OC(F)(F)C(C)=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.38
GAA P10253 1/20 0.37
CYP1A1 P04798 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP1B1 Q16678 1/20 0.37
MAOB P27338 1/20 0.36
AOC3 Q16853 1/20 0.36
EPHX2 P34913 1/20 0.36
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NOS3 P29474 2/20 0.35
NOS1 P29475 2/20 0.35
EDNRB P24530 2/20 0.34
EDNRA P25101 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762035 0.86 PPARA (0.40) PLK1GAACYP1A1CYP1A2CYP1B1
SCHEMBL2343071 0.79 EPHX2 (0.48) CYP1A2EPHX2MAPTKDM4ELMNA
SCHEMBL2336541 0.79 GAA (0.33) PLK1GAACYP1A1CYP1A2CYP1B1
SCHEMBL15912477 0.78 MEN1 (0.43) GAACYP1A2MAOBEPHX2MAPT
SCHEMBL2401014 0.78 GAA (0.44) PLK1GAAMAOBMAPTKDM4E
SCHEMBL514680 0.77 CYP1A1 (0.44) CYP1A1CYP1A2CYP1B1MAOBAOC3
SCHEMBL2337379 0.73 MAOB (0.41) GAACYP1A1CYP1A2CYP1B1MAOB
SCHEMBL9524823 0.73 PPARA (0.62) CYP1A2MAPTKDM4ELMNAPOLB
Water SCHEMBL2397104 0.71 ALDH1A1 (0.42) PLK1GAACYP1A1CYP1A2CYP1B1
SCHEMBL9071228 0.71 PPARA (0.43) PLK1CYP1A1CYP1A2CYP1B1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010056877-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2010-05-20 WO disclosed